Skip to main content
TipRanks
Go Ultimate75% OFF

BONESUPPORT HOLDING AB (BONEX) AI Stock Analysis

15 Followers
SE:BONEX

BONESUPPORT HOLDING AB

(Nasdaq OMX AB:BONEX)

Select Model
Rating:81Outperform
Price Target:SEK 369.00▲(17.67% Upside)
Action:reiterated
Date:10/23/26

The score is primarily supported by BONESUPPORT's exceptional balance sheet, strong profitability, and improving cash generation. Positive earnings momentum and reaffirmed growth guidance add support, while the high P/E ratio and materially overbought technical indicators are the principal risks.

Positive Factors
Accelerating revenue growthRapid sales growth across the core portfolio indicates expanding clinical adoption and commercial reach. Continued momentum in antibiotic-eluting CERAMENT, U.S. accounts, and international markets can strengthen operating leverage and support durable revenue compounding over the next several quarters.
Negative Factors
Historical cash-flow volatilityAlthough current cash generation is strong, the recent inflection leaves less evidence across a full business cycle that conversion will remain consistent. Renewed volatility could constrain investment planning and make future profitability more dependent on sustained procedure growth.

BONESUPPORT HOLDING AB (BONEX) vs. iShares MSCI Sweden ETF (EWD)

-20%0%20%40%60%80%SE:BONEX+58.22%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 2.08B
Dividend Yield
―
Average Volume (3M)
370.65K
Price to Earnings (P/E)
75.9
Beta (1Y)
0.44
Revenue Growth
25.20%
EPS Growth
79.34%
Country
Sweden
Employees
171
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

BONESUPPORT HOLDING AB Business Overview & Revenue Model

Company Description

Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationall...

How the Company Makes Money

BONESUPPORT primarily makes money by selling its CERAMENT-branded bone graft substitute products to hospitals and healthcare providers, generating revenue from procedure-driven usage in orthopedic, trauma, and infection-related bone reconstruction ca...

BONESUPPORT HOLDING AB Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:21.93%|Next Earnings Date:Feb 16, 2027
Earnings Call SentimentPositive

The call was strongly positive, driven by 38% constant-currency sales growth, improved operating margins, strong cash generation, continued U.S. CERAMENT G adoption, favorable CMS reimbursement changes, and positive SOLARIO results. The company also reaffirmed full-year growth guidance and reported progress on CERAMENT V and its spine strategy. Offsetting factors included higher commercial costs, a decline in U.S. gross margin, flat CERAMENT BVF sales, continued go-stop-go adoption patterns, and pending regulatory and clinical milestones.

Positive Updates

Strong Q3 Revenue Growth
Net sales increased from SEK 294 million to SEK 409 million, representing reported growth of 39% and growth of 38% at constant exchange rates versus Q3 2025.

Negative Updates

U.S. Gross Margin Declined Year Over Year
U.S. gross margin declined from approximately 95.3% to 94% year over year. Management attributed the change mainly to increased manufacturing costs, with some impact from U.S. tariffs.

Company Guidance

BONESUPPORT confirmed its previously communicated full-year outlook of sales growth between 33% and 36% in constant currency, based on continued commercial execution on existing baselines and “normalized commercial execution”; management does not expect CMS to have a material impact on revenue in Q4, but expects the ruling to help adoption and access over time and be an important topic in the coming quarters, with positive impact in the quarters to come. Management expects go-stop-go dynamics to continue in Q4 as well as next year, expects U.S. growth of 30%, 40% to require continued investment in the commercial organization, including accelerating administrator-focused hiring in the coming quarter as well as in the next year, and said it expects a formal FDA reply on CERAMENT V sometime in Q4 or Q1, followed by a couple of months between approval and starting sales.

BONESUPPORT HOLDING AB Financial Statement Overview

Summary

Strong profitability, an exceptionally low debt-to-equity ratio of 1.1%, 23.8% ROE, and robust improving free cash flow support a very high score. Moderated revenue growth and historical cash-flow volatility are the main deductions.

Income Statement

91Very Positive

Balance Sheet

96Very Positive

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.40B1.17B898.73M591.08M328.82M212.88M
Gross Profit1.29B1.09B832.25M540.92M300.78M190.03M
EBITDA366.50M288.25M185.75M28.94M-54.34M-72.39M
Net Income271.77M142.15M133.75M245.02M-68.17M-85.53M
Balance Sheet
Total Assets1.17B1.04B879.69M688.82M371.82M343.92M
Cash, Cash Equivalents and Short-Term Investments510.52M377.99M227.00M167.35M201.28M206.46M
Total Debt10.63M11.68M14.59M17.48M17.45M21.42M
Total Liabilities176.35M168.88M152.23M143.64M102.89M78.22M
Stockholders Equity992.49M867.26M727.46M545.18M268.93M265.70M
Cash Flow
Free Cash Flow329.35M216.11M59.92M-24.32M-48.94M-86.84M
Operating Cash Flow333.55M221.30M65.76M-18.26M-46.98M-83.42M
Investing Cash Flow-5.43M-5.88M-6.26M-6.06M-3.28M-3.42M
Financing Cash Flow-199.51M-58.04M-4.81M-6.70M42.78M-61.56M

BONESUPPORT HOLDING AB Technical Analysis

Technical Analysis SentimentPositive
Last Price313.60

Price Trends

50DMA264.52Positive
100DMA243.06Positive
200DMA228.00Positive

Market Momentum

MACD15.33Positive
RSI57.93Neutral
STOCH49.90Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BONEX, the sentiment is Positive. The current price of 313.60 is below the 20-day moving average (MA) of 317.72, above the 50-day MA of 264.52, and above the 200-day MA of 228.00, indicating a neutral trend. The MACD of 15.33 indicates Positive momentum. The RSI at 57.93 is Neutral, neither overbought nor oversold. The STOCH value of 49.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BONEX.

BONESUPPORT HOLDING AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:BONEX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:BONEXSE:BONEX81OutperformSEK 20.65B75.9329.00%―25.20%79.34%
SE:GETI.BSE:GETI.B67NeutralSEK 75.53B26.699.13%1.71%-3.90%37.73%
SE:BACTI.BSE:BACTI.B53NeutralSEK 544.93M86.391.93%―-0.51%―
SE:OSSDSE:OSSD52NeutralSEK 368.38M-7.36――-11.89%-11.85%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:INTEG.BSE:INTEG.B49NeutralSEK 242.60M-5.75-20.71%―1.43%4.98%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SE:BONEXSE:GETI.BSE:BACTI.BSE:INTEG.BSE:PROSE:OSSDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:BONEX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:BONEXBONESUPPORT HOLDING AB313.60116.4059.03%
SE:GETI.BGetinge AB (UK)277.3074.5836.79%
SE:BACTI.BBactiguard Holding AB15.55-3.20-17.07%
SE:INTEG.BIntegrum AB Class B8.27-0.44-5.05%
SE:PROPromimic AB8.35-8.40-50.15%
SE:OSSDOssDsign AB3.33-7.41-68.99%

BONESUPPORT HOLDING AB Corporate Events

BONESUPPORT Posts Strong Q3 Growth as Reimbursement and Clinical Data Bolster Strategy

Oct 22, 2026

BONESUPPORT delivered a strong third quarter, with net sales climbing 39 percent to SEK 408.8 million and adjusted operating profit rising to SEK 139.3 million, supported by robust growth in both its US and Europe & Rest of World segments and gross m...

BONESUPPORT schedules Q3 2026 report and investor webcast

Oct 16, 2026

BONESUPPORT Holding AB will publish its interim report for the third quarter of 2026 on October 22 at 08:00 CEST, underscoring ongoing investor interest in the orthobiologics specialist’s financial performance. The company will follow the release wit...

BONESUPPORT Advances SEK 100m Share Buy-Back to Adjust Capital Structure

Oct 12, 2026

BONESUPPORT Holding AB has continued executing its share buy-back program during the week of October 5–9, 2026, repurchasing a total of 60,000 ordinary shares on Nasdaq Stockholm for approximately SEK 13.8 million. The transactions were carried out b...

BONESUPPORT Expands Share Buy-Back as Treasury Holdings Grow

Sep 28, 2026

BONESUPPORT HOLDING AB has continued its ongoing share buy-back programme, repurchasing 60,000 ordinary shares on Nasdaq Stockholm between 21 and 25 September 2026 for a total of about SEK 12.8 million at an average price of SEK 213.59. These purchas...

BONESUPPORT Builds Momentum for CERAMENT as U.S. Reimbursement and Clinical Data Align

Sep 21, 2026

BONESUPPORT is leveraging its CERAMENT technology platform to address orthopedic infections and bone injuries with injectable, resorbable bone graft substitutes that can deliver local antibiotic therapy. The company’s focus on demonstrating clinical...

BONESUPPORT Expands Share Buy-Back to Strengthen Capital Structure

Sep 21, 2026

BONESUPPORT Holding AB has continued its share buy-back program, repurchasing 68,000 ordinary shares on Nasdaq Stockholm between September 14 and 18, 2026 for a total of about SEK 14.9 million. The program, capped at SEK 100 million and running until...

BONESUPPORT Submits Full Data Package for CERAMENT V De Novo to FDA

Sep 21, 2026

BONESUPPORT has submitted the complete additional data package for its CERAMENT V De Novo application to the U.S. Food and Drug Administration, marking a key regulatory step for its drug-eluting bone graft substitute. The move could strengthen the co...

BONESUPPORT’s SOLARIO Study in NEJM Backs Shorter Antibiotic Courses for Bone Infections

Sep 17, 2026

BONESUPPORT announced that the SOLARIO study, a major multi‑centre randomized trial in orthopedic infections, has been published in The New England Journal of Medicine. The study evaluated whether systemic antibiotic courses could be safely reduced t...

BONESUPPORT Taps Stryker for Australia and New Zealand Expansion

Sep 11, 2026

BONESUPPORT has entered a new distributor partnership with Stryker Australia Pty Ltd, marking its expansion into the New Zealand market and a shift to Stryker as distributor in Australia. The transition, planned for the fourth quarter of 2026, streng...

BONESUPPORT Launches SEK 100m Share Buy-Back to Optimize Capital Structure

Sep 7, 2026

BONESUPPORT Holding AB has initiated a share buy-back programme of up to SEK 100 million to adjust its capital structure to better match capital needs and support shareholder value. The programme, conducted under EU Market Abuse and Safe Harbour regu...

BONESUPPORT Launches SEK 100 Million Share Buy-Back to Adjust Capital Structure

Sep 1, 2026

BONESUPPORT’s board has authorized a share buy-back program of up to SEK 100 million, aiming to optimize the company’s capital structure and enhance shareholder value. The program will run between September 1 and October 30, 2026, with purchases cond...

BONESUPPORT Faces FDA Timeline Extension for CERAMENT V De Novo Submission

Aug 27, 2026

BONESUPPORT has announced that the U.S. Food and Drug Administration has extended the deadline for the additional data package in the De Novo submission for its antibiotic-eluting bone graft product CERAMENT V. The revised timeline stems from a speci...

CMS Grants Higher U.S. Reimbursement for BONESUPPORT’s CERAMENT G

Aug 3, 2026

BONESUPPORT has secured a favorable decision from the U.S. Centers for Medicare & Medicaid Services, which confirmed a DRG reassignment that will place CERAMENT G cases in the highest reimbursing diagnosis-related groups within their clinical categor...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026